Free Trial

Replimune Group (REPL) Competitors

Replimune Group logo
$3.15 +0.05 (+1.61%)
Closing price 04:00 PM Eastern
Extended Trading
$3.13 -0.02 (-0.51%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REPL vs. PTGX, MLTX, IMVT, AAPG, CRNX, KYMR, MOR, HCM, RARE, and ALVO

Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), Ascentage Pharma Group International (AAPG), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

Replimune Group vs. Its Competitors

Replimune Group (NASDAQ:REPL) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 8.8% of Replimune Group shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A-$247.30M-$3.07-1.03
Protagonist Therapeutics$434.43M7.87$275.19M$0.7573.53

Replimune Group currently has a consensus target price of $7.67, suggesting a potential upside of 143.39%. Protagonist Therapeutics has a consensus target price of $66.10, suggesting a potential upside of 19.85%. Given Replimune Group's higher possible upside, equities analysts plainly believe Replimune Group is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Replimune Group
1 Sell rating(s)
8 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.25
Protagonist Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Replimune Group had 43 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 57 mentions for Replimune Group and 14 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Replimune Group's score of -0.37 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Replimune Group
2 Very Positive mention(s)
5 Positive mention(s)
25 Neutral mention(s)
8 Negative mention(s)
4 Very Negative mention(s)
Neutral
Protagonist Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Protagonist Therapeutics has a net margin of 27.04% compared to Replimune Group's net margin of 0.00%. Protagonist Therapeutics' return on equity of 9.22% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Replimune GroupN/A -57.98% -45.21%
Protagonist Therapeutics 27.04%9.22%8.31%

Replimune Group has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500.

Summary

Protagonist Therapeutics beats Replimune Group on 12 of the 15 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REPL vs. The Competition

MetricReplimune GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$238.97M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-1.0321.0428.0720.05
Price / SalesN/A284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book0.588.378.665.87
Net Income-$247.30M-$55.19M$3.25B$258.55M
7 Day Performance-73.95%5.89%4.20%2.23%
1 Month Performance-66.67%17.63%10.82%12.76%
1 Year Performance-69.94%5.09%34.70%19.36%

Replimune Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REPL
Replimune Group
4.4809 of 5 stars
$3.15
+1.6%
$7.67
+143.4%
-69.8%$238.97MN/A-1.03210Trending News
Analyst Forecast
Analyst Revision
Gap Down
PTGX
Protagonist Therapeutics
1.3781 of 5 stars
$55.23
+4.2%
$66.10
+19.7%
+28.3%$3.42B$434.43M73.64120News Coverage
Insider Trade
MLTX
MoonLake Immunotherapeutics
2.1674 of 5 stars
$50.86
+3.8%
$74.50
+46.5%
+20.7%$3.26BN/A-22.112News Coverage
Options Volume
IMVT
Immunovant
1.6052 of 5 stars
$18.59
+2.5%
$36.30
+95.3%
-34.4%$3.18BN/A-6.78120News Coverage
Positive News
Gap Down
AAPG
Ascentage Pharma Group International
N/A$36.20
-5.3%
N/AN/A$3.15B$134.35M0.00600Lockup Expiration
Gap Down
CRNX
Crinetics Pharmaceuticals
3.6692 of 5 stars
$33.02
+3.4%
$69.50
+110.5%
-43.1%$3.09B$1.04M-8.64210
KYMR
Kymera Therapeutics
3.0325 of 5 stars
$44.90
+0.9%
$59.11
+31.7%
+6.9%$2.92B$47.07M-14.48170Positive News
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
HCM
HUTCHMED
2.7778 of 5 stars
$16.23
+1.2%
$19.00
+17.1%
-5.1%$2.83B$630.20M0.001,811Positive News
Analyst Forecast
RARE
Ultragenyx Pharmaceutical
4.3623 of 5 stars
$29.23
-0.9%
$83.64
+186.2%
-39.5%$2.76B$560.23M-4.971,294Upcoming Earnings
Gap Down
High Trading Volume
ALVO
Alvotech
2.6708 of 5 stars
$8.90
+4.5%
$18.00
+102.2%
-21.0%$2.68B$585.60M24.051,032

Related Companies and Tools


This page (NASDAQ:REPL) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners